Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study

John Vellek; Omar H Tarawneh; Syed Faraz Kazim; Oluwafemi P Owodunni; Sophia Arbuiso; Smit Shah; Alis J Dicpinigaitis; Meic H Schmidt; Rohini G McKee; Richard Miskimins; Fawaz Al-Mufti; Christian A Bowers

doi:10.1016/j.wnsx.2024.100367

Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study

World Neurosurg X. 2024 Mar 27:23:100367. doi: 10.1016/j.wnsx.2024.100367. eCollection 2024 Jul.

Affiliations

¹ School of Medicine, New York Medical College, Valhalla, NY, 10595, United States.
² Department of Neurosurgery, University of New Mexico Hospital (UNMH), Albuquerque, NM, 87131, United States.
³ PRISMA Health Richland/University of South Carolina School of Medicine, 1 Medical Park, Suite 230, Columbia, SC, 29203, United States.
⁴ Department of Surgery, University of New Mexico, Albuquerque, NM, 87106, United States.
⁵ Department of Neurosurgery, Westchester Medical Center/New York Medical College, Valhalla, NY, 10595, United States.
⁶ Bowers Neurosurgical Frailty and Outcomes Data Science Lab, Sandy, UT, United States.

Abstract

•Intracranial hemorrhage accounts for two out of every three major intracranial hemorrhages.•Systemic anticoagulation is routinely prescribed for prevention of cerebrovascular accidents.•The FDA approved Andexanet alfa to treat life-threatening bleeding.•Andexanet alfa relationship to outcomes requires further investigation.

Keywords: Andexanet Alfa; Anticoagulation; Intracranial Hemorrhage; Thromboembolism.